pediatric cancer C00-D48
Conditions
Interventions
Group 1: Intervention group includes pediatric cancer patients (4-17 years) under chemotherapy that receive standard care and Whole-body vibration training. Standard care includes the daily offer of p
Sponsors
Deutsche Sporthochschule Köln, Insstitut für Kreislaufforschung und Sportmedizin, Abteilung molekulare und zelluläreSportmedizin
Eligibility
Sex/Gender
All
Age
4 Years to 17 Years
Inclusion criteria
Inclusion criteria: oncological disease, inpatient medical treatment including chemotherapy, age between 4 and 17 years, baseline testing before or 7-14 days after finishing first chemotherapy, medical clearance (approval of the treating physician), written informed consent
Exclusion criteria
Exclusion criteria: prior oncological disease, palliative care, instable osteolysis of lower extremity or pelvis, diagnosed osteonecrosis of lower extremity or pelvis, fracture of lower extremity or pelvis within the last 6 months prior to baseline testing, osteosynthesis, implants in lower extremity, Cerebral metastases, acute prolapse, epilepsy, pregnancy, mental health conditions that do not allow participation in training and/or testing, insufficient German language skills
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility of Whole-body vibration training for pediatric cancer patients undergoing chemotherpy is assessed by drop-Out, compliance to training and adverse events. The study is defined feasible, if (1) less than 50% of all study participants are lost due to drop-out before t1(endpoint) and (2) compliance to training sessions (2x/week) is at least 50%. Adverse events are defined as declines in health that are caused by the whole-body vibration intervention. All Adverse events are documented. | — |
Secondary
| Measure | Time frame |
|---|---|
| Effects of Whole-body vibration training for pediatric cancer patients undergoing chemotherapy on active dorsiflexion range of motion (DF-ROM, goniometer), on isometric dorsiflexion strength (DF-strength, hand-held dynamometer), on mobility (Timed-Up-And-Go Test), on gait (Dartfish Video Gait Analysis) and on physical activity (PA, activity questionnaire) are analysed. Secondary endpoints are assessed before (or 7-14 days after finishing the first chemotherpaie, t0, baseline), after (t1, endpoint) and three month (t2, follow-up) after in-patient medical treatment. Middle points are assessed every three months. | — |
Countries
Germany
Contacts
Public ContactVanessa Oschwald
Deutsche Sporthochschule Köln, Institut für Kreislaufforschung und Sportmedizin, Abteilung molekulare und zelluläre Sportmedizin
Outcome results
None listed